Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Genomics Guidance Paves Way For PKG Firms; Genaissance May Benefit

Executive Summary

Genaissance Pharmaceuticals is developing a pharmacogenomics-based assay for predicting an individual occurrence of agranulocytosis associated with the antipsychotic clozapine (Novartis' Clozaril and generics)

You may also be interested in...



Pharmacogenomics public workshop

FDA public workshop to discuss a draft guidance on the co-development of pharmacogenomics tests with a drug or biologic is planned for April 11-13, 2005 in Bethesda, Md. The draft guidance is expected by the end of the year. The agency published a draft guidance on pharmacogenomics data submissions in November 2003 (1"The Pink Sheet" Nov. 10, 2003, p. 11)...

Pharmacogenomics public workshop

FDA public workshop to discuss a draft guidance on the co-development of pharmacogenomics tests with a drug or biologic is planned for April 11-13, 2005 in Bethesda, Md. The draft guidance is expected by the end of the year. The agency published a draft guidance on pharmacogenomics data submissions in November 2003 (1"The Pink Sheet" Nov. 10, 2003, p. 11)...

Drug Development Too Risky Without Pharmacogenomics, McClellan Says

The future of drug development is too risky without the use of pharmacogenomics-based therapies, FDA Commissioner McClellan told a Drug Information Association workshop Nov. 13

Related Content

UsernamePublicRestriction

Register

PS042781

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel